Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T18:05:15.478Z.
Calculation as of: 2026-10-06T18:05:15.478Z.
Quote observation: 2026-10-06T17:59:19.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6f5be79ac0e7715def3f298c248b41853c7a510be646acbaec4ce361b11b20d4
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$21.49M
PS Ratio
N/A
TTM Avg
252.77
3Y Avg
5169.56
5Y Avg
5169.56
Market Cap
$24.94M
PS Ratio
N/A
TTM Avg
587.77
3Y Avg
330.78
5Y Avg
314.70
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Rein Therapeutics Inc. (RNTX) | $22.88M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.54M | N/A | N/A | N/A | N/A |
| TherapeuticsMD, Inc. (TXMD)vs › | $23.26M | 7.11 | 7.60 | 10.48 | 8.40 |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.11M | 0.38 | 0.46 | 0.28 | 0.24 |
| Modular Medical, Inc. (MODD)vs › | $21.80M | N/A | N/A | N/A | N/A |
| Kyntra Bio, Inc. (KYNB)vs › | $24.07M | 5.21 | 4.70 | 1.77 | 4.39 |
| ABVC BioPharma, Inc. (ABVC)vs › | $24.15M | N/A | 8459.04 | 2873.24 | 1783.28 |
| Quantum BioPharma Ltd. (QNTM)vs › | $21.49M | N/A | 252.77 | 5169.56 | 5169.56 |
| Atossa Therapeutics, Inc. (ATOS)vs › | $24.94M | N/A | 587.77 | 330.78 | 314.70 |
| InspireMD, Inc. (NSPR)vs › | $24.83M | 2.29 | 11.41 | 14.39 | 10.52 |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-14 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-15 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
